Explore our Smartsome™ Platform
Explore our Smartsome™ Platform
Explore our Smartsome™ Platform
The Science of Precision. The Platform for Change.
Smartsome™ is ThanEver’s proprietary exosome platform designed to cross biological barriers like the BBB, enabling targeted treatments for neurodegeneration, immune modulation, and systemic aging. Rooted in decades of science and built for real-world use, it’s a delivery system designed not just to work — but to last.
Smartsome™ Platform Design
A modular, clinically scalable delivery platform built for functional recovery
— from size to source to systemic compatibility.
01
Neural Stem Cell–Derived Functional Source
Smartsome™ originates from highly functional neural lineage stem cells, enabling natural enrichment of neuroprotective and regenerative signals — ideal for brain-targeted therapies.
Smartsome™ Platform Design
A modular, clinically scalable delivery platform built for functional recovery
— from size to source to systemic compatibility.
01
Neural Stem Cell–Derived Functional Source
Smartsome™ originates from highly functional neural lineage stem cells, enabling natural enrichment of neuroprotective and regenerative signals — ideal for brain-targeted therapies.
Smartsome™ Platform Design
A modular, clinically scalable delivery platform built for functional recovery
— from size to source to systemic compatibility.
01
Neural Stem Cell–Derived Functional Source
Smartsome™ originates from highly functional neural lineage stem cells, enabling natural enrichment of neuroprotective and regenerative signals — ideal for brain-targeted therapies.
02
Ultra-Small Particle Size (≈62nm)
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
03
MHC Class II–Negative
Smartsome™ exosomes do not express MHC class II, minimizing immunogenicity and enabling allogeneic, repeatable administration without immune rejection or the need for immunosuppressants.
02
Ultra-Small Particle Size (≈62nm)
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
03
MHC Class II–Negative
Smartsome™ exosomes do not express MHC class II, minimizing immunogenicity and enabling allogeneic, repeatable administration without immune rejection or the need for immunosuppressants.
02
Ultra-Small Particle Size (≈62nm)
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
03
MHC Class II–Negative
Smartsome™ exosomes do not express MHC class II, minimizing immunogenicity and enabling allogeneic, repeatable administration without immune rejection or the need for immunosuppressants.
04
Highly Uniform Particle Distribution
Using advanced purification, Smartsome™ achieves a narrow, consistent size peak (60–80nm), ensuring reproducibility, regulatory compliance, and manufacturing consistency at scale.
05
Trillion-Scale Yield
The platform produces over 1 trillion vesicles per batch, supporting scalable, clinical-grade manufacturing — a key advantage for global deployment and commercial viability.
04
Highly Uniform Particle Distribution
Using advanced purification, Smartsome™ achieves a narrow, consistent size peak (60–80nm), ensuring reproducibility, regulatory compliance, and manufacturing consistency at scale.
05
Trillion-Scale Yield
The platform produces over 1 trillion vesicles per batch, supporting scalable, clinical-grade manufacturing — a key advantage for global deployment and commercial viability.
04
Highly Uniform Particle Distribution
Using advanced purification, Smartsome™ achieves a narrow, consistent size peak (60–80nm), ensuring reproducibility, regulatory compliance, and manufacturing consistency at scale.
05
Trillion-Scale Yield
The platform produces over 1 trillion vesicles per batch, supporting scalable, clinical-grade manufacturing — a key advantage for global deployment and commercial viability.
06
500× Functional Molecule Enrichment
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
07
GMP-Compatible Manufacturing Process
The platform is designed for reproducibility, sterility, and scalability under GMP conditions — supporting both clinical trials and commercial production.
06
500× Functional Molecule Enrichment
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
07
GMP-Compatible Manufacturing Process
The platform is designed for reproducibility, sterility, and scalability under GMP conditions — supporting both clinical trials and commercial production.
06
500× Functional Molecule Enrichment
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
07
GMP-Compatible Manufacturing Process
The platform is designed for reproducibility, sterility, and scalability under GMP conditions — supporting both clinical trials and commercial production.
+
Human + Companion Animal Dual Pathway
Smartsome™ is currently being deployed in both human and companion-animal indications, accelerating early validation and creating a parallel proof-of-concept pipeline for faster market feedback.
+
No Observed Side Effects in Preclinical Studies
Validated in multiple internal and third-party safety studies, Smartsome™ demonstrated no immune-related toxicity, off-target inflammation, or adverse effects, even at high doses.
+
Human + Companion Animal Dual Pathway
Smartsome™ is currently being deployed in both human and companion-animal indications, accelerating early validation and creating a parallel proof-of-concept pipeline for faster market feedback.
+
No Observed Side Effects in Preclinical Studies
Validated in multiple internal and third-party safety studies, Smartsome™ demonstrated no immune-related toxicity, off-target inflammation, or adverse effects, even at high doses.
+
Human + Companion Animal Dual Pathway
Smartsome™ is currently being deployed in both human and companion-animal indications, accelerating early validation and creating a parallel proof-of-concept pipeline for faster market feedback.
+
No Observed Side Effects in Preclinical Studies
Validated in multiple internal and third-party safety studies, Smartsome™ demonstrated no immune-related toxicity, off-target inflammation, or adverse effects, even at high doses.
Smartsome™
by the Numbers
Smartsome™
by the Numbers
Smartsome™
by the Numbers
Smartsome™ isn’t just a concept — it’s a platform with quantifiable, measurable, and translational strengths.
From nanoscale particle size to GMP-compatible yield, each design choice translates directly into clinical and commercial readiness.
62nm
62nm
62nm
Particle Size (-55%)
500X+
500X+
500X+
Functional Molecules
1 Trillion+
1 Trillion+
1 Trillion+
2000X+ Exosome Yield per Batch
Immune-Silent
Immune-Silent
Immune-Silent
MHC II–negative, safe for repeat allogeneic use
Clinical-Grade
Clinical-Grade
Clinical-Grade
Clinical-Grade Scalability
FAQ's
FAQ's
FAQ's
What makes Smartsome™ different from other exosome platforms?
Can Smartsome™ be used allogeneically without immune rejection?
What stage is your pipeline currently at?
What specific problems does Smartsome™ solve that other platforms don’t?
How do you validate the efficacy of your platform?
How is your manufacturing process designed for scalability?
What’s your go-to-market strategy?
Is ThanEver open to partnerships or investment?
What makes Smartsome™ different from other exosome platforms?
Can Smartsome™ be used allogeneically without immune rejection?
What stage is your pipeline currently at?
What specific problems does Smartsome™ solve that other platforms don’t?
How do you validate the efficacy of your platform?
How is your manufacturing process designed for scalability?
What’s your go-to-market strategy?
Is ThanEver open to partnerships or investment?
What makes Smartsome™ different from other exosome platforms?
Can Smartsome™ be used allogeneically without immune rejection?
What stage is your pipeline currently at?
What specific problems does Smartsome™ solve that other platforms don’t?
How do you validate the efficacy of your platform?
How is your manufacturing process designed for scalability?
What’s your go-to-market strategy?
Is ThanEver open to partnerships or investment?
We're here to build the future
of brain health — together.
Let’s talk about what’s possible in translational biotech, cognitive longevity, and functional recovery.
We're here to build the future
of brain health — together.
Let’s talk about what’s possible in translational biotech, cognitive longevity, and functional recovery.
We're here to build the future
of brain health — together.
Let’s talk about what’s possible in translational biotech, cognitive longevity, and functional recovery.
Explore our Smartsome™ Platform
Explore our Smartsome™ Platform
Explore our Smartsome™ Platform
The Science of Precision. The Platform for Change.
Smartsome™ is ThanEver’s proprietary exosome platform designed to cross biological barriers like the BBB, enabling targeted treatments for neurodegeneration, immune modulation, and systemic aging. Rooted in decades of science and built for real-world use, it’s a delivery system designed not just to work — but to last.
Smartsome™ Platform Design
A modular, clinically scalable delivery platform built for functional recovery
— from size to source to systemic compatibility.
01
Neural Stem Cell–Derived Functional Source
Smartsome™ originates from highly functional neural lineage stem cells, enabling natural enrichment of neuroprotective and regenerative signals — ideal for brain-targeted therapies.
Smartsome™ Platform Design
A modular, clinically scalable delivery platform built for functional recovery
— from size to source to systemic compatibility.
01
Neural Stem Cell–Derived Functional Source
Smartsome™ originates from highly functional neural lineage stem cells, enabling natural enrichment of neuroprotective and regenerative signals — ideal for brain-targeted therapies.
Smartsome™ Platform Design
A modular, clinically scalable delivery platform built for functional recovery
— from size to source to systemic compatibility.
01
Neural Stem Cell–Derived Functional Source
Smartsome™ originates from highly functional neural lineage stem cells, enabling natural enrichment of neuroprotective and regenerative signals — ideal for brain-targeted therapies.
02
Ultra-Small Particle Size (≈62nm)
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
03
MHC Class II–Negative
Smartsome™ exosomes do not express MHC class II, minimizing immunogenicity and enabling allogeneic, repeatable administration without immune rejection or the need for immunosuppressants.
02
Ultra-Small Particle Size (≈62nm)
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
03
MHC Class II–Negative
Smartsome™ exosomes do not express MHC class II, minimizing immunogenicity and enabling allogeneic, repeatable administration without immune rejection or the need for immunosuppressants.
02
Ultra-Small Particle Size (≈62nm)
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
03
MHC Class II–Negative
Smartsome™ exosomes do not express MHC class II, minimizing immunogenicity and enabling allogeneic, repeatable administration without immune rejection or the need for immunosuppressants.
04
Highly Uniform Particle Distribution
Using advanced purification, Smartsome™ achieves a narrow, consistent size peak (60–80nm), ensuring reproducibility, regulatory compliance, and manufacturing consistency at scale.
05
Trillion-Scale Yield
The platform produces over 1 trillion vesicles per batch, supporting scalable, clinical-grade manufacturing — a key advantage for global deployment and commercial viability.
04
Highly Uniform Particle Distribution
Using advanced purification, Smartsome™ achieves a narrow, consistent size peak (60–80nm), ensuring reproducibility, regulatory compliance, and manufacturing consistency at scale.
05
Trillion-Scale Yield
The platform produces over 1 trillion vesicles per batch, supporting scalable, clinical-grade manufacturing — a key advantage for global deployment and commercial viability.
04
Highly Uniform Particle Distribution
Using advanced purification, Smartsome™ achieves a narrow, consistent size peak (60–80nm), ensuring reproducibility, regulatory compliance, and manufacturing consistency at scale.
05
Trillion-Scale Yield
The platform produces over 1 trillion vesicles per batch, supporting scalable, clinical-grade manufacturing — a key advantage for global deployment and commercial viability.
06
500× Functional Molecule Enrichment
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
07
GMP-Compatible Manufacturing Process
The platform is designed for reproducibility, sterility, and scalability under GMP conditions — supporting both clinical trials and commercial production.
06
500× Functional Molecule Enrichment
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
07
GMP-Compatible Manufacturing Process
The platform is designed for reproducibility, sterility, and scalability under GMP conditions — supporting both clinical trials and commercial production.
06
500× Functional Molecule Enrichment
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
07
GMP-Compatible Manufacturing Process
The platform is designed for reproducibility, sterility, and scalability under GMP conditions — supporting both clinical trials and commercial production.
+
Human + Companion Animal Dual Pathway
Smartsome™ is currently being deployed in both human and companion-animal indications, accelerating early validation and creating a parallel proof-of-concept pipeline for faster market feedback.
+
No Observed Side Effects in Preclinical Studies
Validated in multiple internal and third-party safety studies, Smartsome™ demonstrated no immune-related toxicity, off-target inflammation, or adverse effects, even at high doses.
+
Human + Companion Animal Dual Pathway
Smartsome™ is currently being deployed in both human and companion-animal indications, accelerating early validation and creating a parallel proof-of-concept pipeline for faster market feedback.
+
No Observed Side Effects in Preclinical Studies
Validated in multiple internal and third-party safety studies, Smartsome™ demonstrated no immune-related toxicity, off-target inflammation, or adverse effects, even at high doses.
+
Human + Companion Animal Dual Pathway
Smartsome™ is currently being deployed in both human and companion-animal indications, accelerating early validation and creating a parallel proof-of-concept pipeline for faster market feedback.
+
No Observed Side Effects in Preclinical Studies
Validated in multiple internal and third-party safety studies, Smartsome™ demonstrated no immune-related toxicity, off-target inflammation, or adverse effects, even at high doses.
Smartsome™
by the Numbers
Smartsome™
by the Numbers
Smartsome™
by the Numbers
Smartsome™ isn’t just a concept — it’s a platform with quantifiable, measurable, and translational strengths.
From nanoscale particle size to GMP-compatible yield, each design choice translates directly into clinical and commercial readiness.
62nm
62nm
62nm
Particle Size (-55%)
500X+
500X+
500X+
Functional Molecules
1 Trillion+
1 Trillion+
1 Trillion+
2000X+ Exosome Yield per Batch
Immune-Silent
Immune-Silent
Immune-Silent
MHC II–negative, safe for repeat allogeneic use
Clinical-Grade
Clinical-Grade
Clinical-Grade
Clinical-Grade Scalability
FAQ's
FAQ's
FAQ's
What makes Smartsome™ different from other exosome platforms?
Can Smartsome™ be used allogeneically without immune rejection?
What stage is your pipeline currently at?
What specific problems does Smartsome™ solve that other platforms don’t?
How do you validate the efficacy of your platform?
How is your manufacturing process designed for scalability?
What’s your go-to-market strategy?
Is ThanEver open to partnerships or investment?
What makes Smartsome™ different from other exosome platforms?
Can Smartsome™ be used allogeneically without immune rejection?
What stage is your pipeline currently at?
What specific problems does Smartsome™ solve that other platforms don’t?
How do you validate the efficacy of your platform?
How is your manufacturing process designed for scalability?
What’s your go-to-market strategy?
Is ThanEver open to partnerships or investment?
What makes Smartsome™ different from other exosome platforms?
Can Smartsome™ be used allogeneically without immune rejection?
What stage is your pipeline currently at?
What specific problems does Smartsome™ solve that other platforms don’t?
How do you validate the efficacy of your platform?
How is your manufacturing process designed for scalability?
What’s your go-to-market strategy?
Is ThanEver open to partnerships or investment?
We're here to build the future
of brain health — together.
Let’s talk about what’s possible in translational biotech, cognitive longevity, and functional recovery.
We're here to build the future
of brain health — together.
Let’s talk about what’s possible in translational biotech, cognitive longevity, and functional recovery.
We're here to build the future
of brain health — together.
Let’s talk about what’s possible in translational biotech, cognitive longevity, and functional recovery.
Explore our Smartsome™ Platform
Explore our Smartsome™ Platform
Explore our Smartsome™ Platform
The Science of Precision. The Platform for Change.
Smartsome™ is ThanEver’s proprietary exosome platform designed to cross biological barriers like the BBB, enabling targeted treatments for neurodegeneration, immune modulation, and systemic aging. Rooted in decades of science and built for real-world use, it’s a delivery system designed not just to work — but to last.
Smartsome™ Platform Design
A modular, clinically scalable delivery platform built for functional recovery
— from size to source to systemic compatibility.
01
Neural Stem Cell–Derived Functional Source
Smartsome™ originates from highly functional neural lineage stem cells, enabling natural enrichment of neuroprotective and regenerative signals — ideal for brain-targeted therapies.
Smartsome™ Platform Design
A modular, clinically scalable delivery platform built for functional recovery
— from size to source to systemic compatibility.
01
Neural Stem Cell–Derived Functional Source
Smartsome™ originates from highly functional neural lineage stem cells, enabling natural enrichment of neuroprotective and regenerative signals — ideal for brain-targeted therapies.
Smartsome™ Platform Design
A modular, clinically scalable delivery platform built for functional recovery
— from size to source to systemic compatibility.
01
Neural Stem Cell–Derived Functional Source
Smartsome™ originates from highly functional neural lineage stem cells, enabling natural enrichment of neuroprotective and regenerative signals — ideal for brain-targeted therapies.
02
Ultra-Small Particle Size (≈62nm)
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
03
MHC Class II–Negative
Smartsome™ exosomes do not express MHC class II, minimizing immunogenicity and enabling allogeneic, repeatable administration without immune rejection or the need for immunosuppressants.
02
Ultra-Small Particle Size (≈62nm)
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
03
MHC Class II–Negative
Smartsome™ exosomes do not express MHC class II, minimizing immunogenicity and enabling allogeneic, repeatable administration without immune rejection or the need for immunosuppressants.
02
Ultra-Small Particle Size (≈62nm)
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
03
MHC Class II–Negative
Smartsome™ exosomes do not express MHC class II, minimizing immunogenicity and enabling allogeneic, repeatable administration without immune rejection or the need for immunosuppressants.
04
Highly Uniform Particle Distribution
Using advanced purification, Smartsome™ achieves a narrow, consistent size peak (60–80nm), ensuring reproducibility, regulatory compliance, and manufacturing consistency at scale.
05
Trillion-Scale Yield
The platform produces over 1 trillion vesicles per batch, supporting scalable, clinical-grade manufacturing — a key advantage for global deployment and commercial viability.
04
Highly Uniform Particle Distribution
Using advanced purification, Smartsome™ achieves a narrow, consistent size peak (60–80nm), ensuring reproducibility, regulatory compliance, and manufacturing consistency at scale.
05
Trillion-Scale Yield
The platform produces over 1 trillion vesicles per batch, supporting scalable, clinical-grade manufacturing — a key advantage for global deployment and commercial viability.
04
Highly Uniform Particle Distribution
Using advanced purification, Smartsome™ achieves a narrow, consistent size peak (60–80nm), ensuring reproducibility, regulatory compliance, and manufacturing consistency at scale.
05
Trillion-Scale Yield
The platform produces over 1 trillion vesicles per batch, supporting scalable, clinical-grade manufacturing — a key advantage for global deployment and commercial viability.
06
500× Functional Molecule Enrichment
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
07
GMP-Compatible Manufacturing Process
The platform is designed for reproducibility, sterility, and scalability under GMP conditions — supporting both clinical trials and commercial production.
06
500× Functional Molecule Enrichment
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
07
GMP-Compatible Manufacturing Process
The platform is designed for reproducibility, sterility, and scalability under GMP conditions — supporting both clinical trials and commercial production.
06
500× Functional Molecule Enrichment
Smartsome™ carries up to 500× more functional biomolecules (e.g., NTFs, GFs, anti-inflammatory factors) compared to standard exosomes, significantly enhancing therapeutic efficacy.
07
GMP-Compatible Manufacturing Process
The platform is designed for reproducibility, sterility, and scalability under GMP conditions — supporting both clinical trials and commercial production.
+
Human + Companion Animal Dual Pathway
Smartsome™ is currently being deployed in both human and companion-animal indications, accelerating early validation and creating a parallel proof-of-concept pipeline for faster market feedback.
+
No Observed Side Effects in Preclinical Studies
Validated in multiple internal and third-party safety studies, Smartsome™ demonstrated no immune-related toxicity, off-target inflammation, or adverse effects, even at high doses.
+
Human + Companion Animal Dual Pathway
Smartsome™ is currently being deployed in both human and companion-animal indications, accelerating early validation and creating a parallel proof-of-concept pipeline for faster market feedback.
+
No Observed Side Effects in Preclinical Studies
Validated in multiple internal and third-party safety studies, Smartsome™ demonstrated no immune-related toxicity, off-target inflammation, or adverse effects, even at high doses.
+
Human + Companion Animal Dual Pathway
Smartsome™ is currently being deployed in both human and companion-animal indications, accelerating early validation and creating a parallel proof-of-concept pipeline for faster market feedback.
+
No Observed Side Effects in Preclinical Studies
Validated in multiple internal and third-party safety studies, Smartsome™ demonstrated no immune-related toxicity, off-target inflammation, or adverse effects, even at high doses.
Smartsome™
by the Numbers
Smartsome™
by the Numbers
Smartsome™
by the Numbers
Smartsome™ isn’t just a concept — it’s a platform with quantifiable, measurable, and translational strengths.
From nanoscale particle size to GMP-compatible yield, each design choice translates directly into clinical and commercial readiness.
62nm
62nm
62nm
Particle Size (-55%)
500X+
500X+
500X+
Functional Molecules
1 Trillion+
1 Trillion+
1 Trillion+
2000X+ Exosome Yield per Batch
Immune-Silent
Immune-Silent
Immune-Silent
MHC II–negative, safe for repeat allogeneic use
Clinical-Grade
Clinical-Grade
Clinical-Grade
Clinical-Grade Scalability
FAQ's
FAQ's
FAQ's
What makes Smartsome™ different from other exosome platforms?
Can Smartsome™ be used allogeneically without immune rejection?
What stage is your pipeline currently at?
What specific problems does Smartsome™ solve that other platforms don’t?
How do you validate the efficacy of your platform?
How is your manufacturing process designed for scalability?
What’s your go-to-market strategy?
Is ThanEver open to partnerships or investment?
What makes Smartsome™ different from other exosome platforms?
Can Smartsome™ be used allogeneically without immune rejection?
What stage is your pipeline currently at?
What specific problems does Smartsome™ solve that other platforms don’t?
How do you validate the efficacy of your platform?
How is your manufacturing process designed for scalability?
What’s your go-to-market strategy?
Is ThanEver open to partnerships or investment?
What makes Smartsome™ different from other exosome platforms?
Can Smartsome™ be used allogeneically without immune rejection?
What stage is your pipeline currently at?
What specific problems does Smartsome™ solve that other platforms don’t?
How do you validate the efficacy of your platform?
How is your manufacturing process designed for scalability?
What’s your go-to-market strategy?
Is ThanEver open to partnerships or investment?
We're here to build the future
of brain health — together.
Let’s talk about what’s possible in translational biotech, cognitive longevity, and functional recovery.
We're here to build the future
of brain health — together.
Let’s talk about what’s possible in translational biotech, cognitive longevity, and functional recovery.
We're here to build the future
of brain health — together.
Let’s talk about what’s possible in translational biotech, cognitive longevity, and functional recovery.